AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 08:49:40 2024-04-30 am EDT			5-day change	1st Jan Change
12,046 ^GBX	+0.18%		+7.26%	+14.02%

Apr. 29	J&J, Bristol Myers lose challenges to US drug price negotiation program	RE
Apr. 29	European Equities Close Mixed in Monday Trading; Economic Sentiment Falls in April; Lawsuit Dents Deutsche Bank Shares	MT

ASTRAZENECA : JP Morgan keeps its Buy rating

April 04, 2024 at 05:47 am EDT

In a research note published by James Gordon, JP Morgan advises its customers to buy the stock. The target price is still set at GBX 13000.

Latest news about AstraZeneca PLC

J&J, Bristol Myers lose challenges to US drug price negotiation program	Apr. 29	RE
European Equities Close Mixed in Monday Trading; Economic Sentiment Falls in April; Lawsuit Dents Deutsche Bank Shares	Apr. 29	MT
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed	Apr. 29	MT
AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement	Apr. 29	MT
ASTRAZENECA : JP Morgan maintains a Buy rating	Apr. 29	ZD
AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow	Apr. 29	CI
Deutsche Bank likes Frasers; Barclays cuts JD	Apr. 29	AN
AstraZeneca makes progress with Truqap and Enhertu cancer treatments	Apr. 29	AN
AstraZeneca: CHMP green light for Truqap + Faslodex	Apr. 29	CF
AstraZeneca: new positive data for Enhertu	Apr. 29	CF
FTSE 100 continues record run boosted by Anglo American, AstraZeneca	Apr. 29	RE
AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study	Apr. 29	MT
AstraZeneca's Truqap Plus Faslodex Breast Cancer Treatment Bags EU Approval Recommendation	Apr. 29	MT
Hipgnosis Songs Fund backs new Blackstone bid	Apr. 29	AN
ASTRAZENECA : DZ Bank sticks Neutral	Apr. 26	ZD
ASTRAZENECA : UBS keeps a Sell rating	Apr. 26	ZD
ASTRAZENECA : Deutsche Bank remains Neutral	Apr. 26	ZD
ASTRAZENECA : Gets a Buy rating from Barclays	Apr. 26	ZD
Barclays Raises AstraZeneca PT, Affirms at Overweight	Apr. 26	MT
Peel Hunt cuts ConvaTec to 'reduce'	Apr. 26	AN
THE FTSE 100 is on a roll	Apr. 26
Health Care Drops Amid Mixed Earnings -- Health Care Roundup	Apr. 25	DJ
Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 25	MT
Sector Update: Health Care Stocks Drop in Afternoon Trading	Apr. 25	MT
Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump	Apr. 25	MT

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-04-29 - Roadshow - Day 2

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

150.9 USD

Average target price

164.3 USD

Spread / Average Target

+8.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+14.02%	234B
ELI LILLY AND COMPANY	+26.47%	664B
NOVO NORDISK A/S	+28.29%	567B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.35%	330B
ABBVIE INC.	+4.23%	286B
NOVARTIS AG	+4.89%	199B
ROCHE HOLDING AG	-10.06%	196B
AMGEN INC.	-4.04%	148B
PFIZER, INC.	-10.94%	145B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : JP Morgan keeps its Buy rating

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals